Find Small Cell Lung Cancer (SCLC) Clinical Trials Near You
A Multi-center, Open-Label, Phase Ib/II Study of YL202 in Combination With Anti-tumor Therapy to Evaluate the Safety, Tolerability, and Efficacy in Patients With Advanced Solid Tumors
Status: Recruiting
Location: See all (20) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
This is a multicenter, open-label, phase Ib/II study of YL202 in combination with other anti-tumor therapies to Evaluate the Safety, Tolerability, and Efficacy in Patients with Advanced Solid Tumors
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Informed of the study before the start of the study and voluntarily sign their name and date in the informed consent form (ICF)
• Able and willing to comply with protocol visits and procedures
• Aged between 18 to 75 years
• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
• Previously treated by standard treatment or have not been treated for metastatic setting;
• Adequate organ and bone marrow function.
• Have at least 1 extracranial measurable tumor lesion.
Anhui Provincial Hospital(The First Affiliated Hospital of Ustc)
NOT_YET_RECRUITING
Hefei
Affiliated Zhongshan Hospital Dalian University
NOT_YET_RECRUITING
Jinan
The First Affiliated Hospital of Henan University of Science and Technology
NOT_YET_RECRUITING
Luoyang
Meizhou People's Hospital（Huangtang Hospital）Meizhou Academy of Medical Sciences
NOT_YET_RECRUITING
Meizhou
Jiangxi Cancer Hospital
NOT_YET_RECRUITING
Nanchang
Jiangsu Province Hospital（The First Affiliated Hospital With Nanjing Medical University, Jiangsu Women And Children Health Hospital)
NOT_YET_RECRUITING
Nanjing
Ghang xi Medical University Cancer Hospital
NOT_YET_RECRUITING
Nanning
Fudan University Shanghai Cancer Center
RECRUITING
Shanghai
Liaoning cancer hospital &institute
NOT_YET_RECRUITING
Shenyang
Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital
NOT_YET_RECRUITING
Sichuan
Shanxi Cancer Hospital
NOT_YET_RECRUITING
Taiyuan
Tianjin Cancer Hospital Airport Hospital
NOT_YET_RECRUITING
Tianjin
Xiangyang Central Hospital
NOT_YET_RECRUITING
Xiangyang
Contact Information
Primary
Ning Wang, MM
info@medilinkthera.com
+86 0512-62858368
Time Frame
Start Date:2025-09-02
Estimated Completion Date:2027-11-30
Participants
Target number of participants:414
Treatments
Experimental: YL202 in combination with Toripalimab
Part 1 (dose escalation stage and backfill stage) \& Part 3 (dose expansion stage): YL202 for injection in combination with Toripalimab injection
Experimental: YL202 in combination with Furmonertinib Mesilate
Part 2 (dose escalation stage and backfill stage) \& Part 4 (dose expansion stage): YL202 for injection in combination with Furmonertinib Mesilate Tablets